All lobbying filings

FORBES-TATE

Lobbying for ELI LILLY AND COMPANY FKA LILLY USA, LLC · Pharmaceutical Company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Indiana · House · Senate · $50,000.00 income · posted Jan 18, 2026

Official filing document

Bills named in this filing 4

HR 5316
Drug Shortage Compounding Patient Access Act of 2025
HR 6509
SAFE Drugs Act of 2025
HR 4231
Treat and Reduce Obesity Act of 2025
S 1973
Treat and Reduce Obesity Act of 2025

Lobbying activity 3

Health Issues

Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025.

Medicare/Medicaid

Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.

Budget/Appropriations

Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.